AVI Polymers Limited, in its Board of Directors meeting held on Thursday, May 7, 2026, unanimously approved two significant strategic initiatives — a transformational acquisition via a share swap mechanism and an expansion of its core business objects through amendments to its Memorandum of Association (MOA). The disclosures were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and were signed by Chintan Yashwantbhai Patel, Managing Director (DIN: 10774473).

Strategic Acquisition of 90% Stake in JVTR Consultants

The board approved the issuance of equity shares through a share swap on the basis of a Preferential Issue, specifically designed to execute the acquisition of a 90% stake in JVTR Consultants Private Limited. The transaction is being evaluated at an indicative valuation of ₹500 Crore. Key details of the approved acquisition are outlined below:

The proposed fund raise and subsequent share swap remain subject to the finalization of definitive terms and conditions, comprehensive due diligence, and the execution of definitive agreements. The transaction also requires the affirmative vote of shareholders and approvals from requisite regulatory authorities, as applicable.

MOA Amendment to Expand into Technology Sector

To align with the company's structural pivot into the technology sector and seamlessly integrate the acquisition, the board also approved the addition of new objects in the Memorandum of Association, subject to shareholder approval. The newly added business domains include:

• Information technology services
• Software development
• System integration
• Digital platforms
• Allied technology services and related activities

This expansion of the MOA signals AVI Polymers' intent to broaden its operational scope beyond its existing polymer-related business activities into the technology sector.

Board Meeting Details

The meeting of the Board of Directors commenced at 11:00 AM and concluded at 11:30 AM on May 7, 2026. In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of AVI Polymers Limited remained closed from May 04, 2026 until the expiry of 48 hours from the conclusion of the Board meeting.

AVI Polymers Limited has filed a business update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, dated May 06, 2026, announcing exceptional early traction for its HealthTech AI platform, Ashwini Healthcare AI, available at www.ashwini.tech . The company reports a highly engaged waitlist of over 5,620 registered users since the platform's soft launch, which it states validates its strategic pivot into scalable digital platforms.

Platform Overview and Early Adoption

Ashwini Healthcare AI has been built on a Software-as-a-Service (SaaS) architecture. According to the company's disclosure, the organic traction witnessed since launch has been described as remarkable, with the waitlist of 5,620 users cited as strong validation of the platform's market fit. The company has invited stakeholders to view the platform live at its official portal, www.ashwini.tech .

SaaS Unit Economics and Year-1 Revenue Projections

The company has outlined its monetization model based on an annual recurring revenue structure. The following table summarises the key SaaS metrics and near-term revenue projections disclosed by the company:

The platform operates on an annual subscription priced at ₹999/year, designed for penetration in the domestic retail market. Applying industry-standard health and wellness SaaS conversion metrics of 8% to 15% to the current waitlist, the company projects an initial cohort of 600 to 900 active paying subscribers, establishing a baseline Year-1 ARR of approximately ₹6.00 Lakhs to ₹9.00 Lakhs. The platform's internal operational target is to achieve and maintain an annual retention rate of 65% to 70%.

Tiered Growth Milestones Toward ₹1 Crore ARR

The company has outlined a phased growth roadmap with specific subscriber and revenue targets. The key milestones are detailed below:

• Phase 1 targets scaling the active user base to approximately 10,000 paying subscribers, which the company states will unlock a ₹1 Crore ARR run-rate and position Ashwini Healthcare AI among top-performing early-stage SaaS platforms in the Indian market.
• Phase 2 targets an expansion of the ecosystem to 80,000 – 1,20,000 paying subscribers, with a corresponding ARR target of ₹8 Crore to ₹12 Crore, which the company describes as representative of standard Series-A valuation metrics.

Disclosure Context

The business update was filed by Managing Director Chintan Yashwantbhai Patel (DIN: 10774473) on May 06, 2026, under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. The company has requested BSE Limited to place the update on record and disseminate it for the information of investors and the general public. AVI Polymers Limited is headquartered at Shop No. 02, 5th Floor, Roshpa Tower, Main Road Ranchi, Jharkhand, with its corporate office in Anand, Gujarat.